|
Global developmental delay
|
0.110 |
Biomarker
|
disease |
BEFREE |
Lactic acidosis and developmental delay due to deficiency of E3 binding protein (protein X) of the pyruvate dehydrogenase complex.
|
15303005 |
2004 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, two freshly isolated human pancreatic cancer specimens had significantly increased levels of PDX-1.
|
14746841 |
2004 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer.
|
23828595 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of PDX-1 expression inhibits pancreatic cancer cell growth in vitro and in vivo, implying its use as a potential therapeutic target for the treatment of pancreatic cancer.
|
18665085 |
2008 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 co-delivery.
|
17161985 |
2007 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experiments were performed in a genetically engineered mouse model of pancreatic cancer (KPC mice: LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx-1-Cre).
|
28715967 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, PDX-1 protein was found in all six freshly isolated human pancreas cancer specimens and two liver metastasis samples that were group-tested, suggesting the feasibility of using RIP-TK gene therapy in humans.
|
15457366 |
2004 |
|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre.
|
28971839 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PDX-1: demonstration of oncogenic properties in pancreatic cancer.
|
20886630 |
2011 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer.
|
29309817 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx-1-Cre (KPC) mouse model represents an established and frequently used transgenic model to evaluate novel therapies in pancreatic cancer.
|
29683461 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In all but two patients with pancreatic cancer, PDX-1 was expressed and was found positive in 7 patients with pancreatic cancer in which cytology was negative.
|
25454709 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further explore the oncogenic activity of Aurora A kinase while attempting to develop a useful mouse model for pancreatic cancer, Aurora A kinase was targeted to pancreatic duodenal homeobox gene-1 (Pdx-1)-positive cells.
|
18815537 |
2008 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer.
|
29309817 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experiments were performed in a genetically engineered mouse model of pancreatic cancer (KPC mice: LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx-1-Cre).
|
28715967 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, PDX-1 protein was found in all six freshly isolated human pancreas cancer specimens and two liver metastasis samples that were group-tested, suggesting the feasibility of using RIP-TK gene therapy in humans.
|
15457366 |
2004 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, two freshly isolated human pancreatic cancer specimens had significantly increased levels of PDX-1.
|
14746841 |
2004 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
PDX-1: demonstration of oncogenic properties in pancreatic cancer.
|
20886630 |
2011 |
|
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre.
|
28971839 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx-1-Cre (KPC) mouse model represents an established and frequently used transgenic model to evaluate novel therapies in pancreatic cancer.
|
29683461 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In all but two patients with pancreatic cancer, PDX-1 was expressed and was found positive in 7 patients with pancreatic cancer in which cytology was negative.
|
25454709 |
2015 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of PDX-1 expression inhibits pancreatic cancer cell growth in vitro and in vivo, implying its use as a potential therapeutic target for the treatment of pancreatic cancer.
|
18665085 |
2008 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 co-delivery.
|
17161985 |
2007 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further explore the oncogenic activity of Aurora A kinase while attempting to develop a useful mouse model for pancreatic cancer, Aurora A kinase was targeted to pancreatic duodenal homeobox gene-1 (Pdx-1)-positive cells.
|
18815537 |
2008 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer.
|
23828595 |
2013 |